NVO is trading 4.7% up at $49.65 in after-hours trading after Novo Nordisk secured a South African High Court order halting sales of unapproved Ozempic and Wegovy copies.
- The ruling reinforces control over the company's key semaglutide franchise and eases competitive and regulatory concerns regarding its obesity and diabetes drugs.
- The price action extends a sharp rebound for the stock from its mid-June lows.